OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8.5 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).
Alternative Splicing: A Key Process in Development and Disease
Submission Deadline: December 31, 2020 (Open) Submit Now
Michael R. Ladomery, PhD
Faculty of Health and Applied Sciences, University of the West of England, Bristol; Frenchay Campus,
Coldharbour Lane, Bristol BS16 1QY, UK
Research Interests: RNA biology; alternative splicing; noncoding RNA; RNA-based cancer therapies
About this topic
Soon after the discovery of pre-mRNA splicing in the late 1970s it became apparent that transcripts can be ‘alternatively spliced’ across eukaryotes. The main modes of alternative splicing are cassette exons that can be skipped; alternative splice sites that change the boundaries of exons; mutually exclusive exons; and retained introns. It is thought that over 94% of multi-exonic genes are alternatively spliced in humans. Alternative splicing is affected by regulatory sequences present within exons and introns. These are recognised by a multitude of splice factors that regulate splicing machinery access. Alternative splicing means that genes can express proteins with strikingly different characteristics. These can even have antagonistic properties (for example pro- or anti-apoptotic splice isoforms). It is then not surprising to find that alternative splicing plays a key role in development and that mutations that disrupt alternative splicing contribute to disease. Alternative splicing research provides enormous opportunities to understand fundamental biological processes; it also presents a new context in which to develop novel therapies.
Title: Alternative splicing in neuroendocrine prostate cancer
Author: Jennifer Munkley
Title: Alternative splicing during activation of immunoglobulin class switching in human B cells
Author: Youming Zhang
Title: Environmentally induced alternative splicing
Author: Fatima Smagulova
Title: Translating RNA splicing analysis into diagnosis and therapy
Authors: Andrew Douglas, Diana Baralle
Title: The CLK splice factor kinases: a new target for therapy?
Authors: Ahmed Hussein, Michael Ladomery
Title: Dysregulation of scaRNA expression leads to alternative splicing of mRNA, contributing to congenital heart defects
Authors: Douglas C. Bittel, et al
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.